You are using an old browser, click here to download PDF
PDF Container
Tools
The Role of Biosimilar and Orphan Drugs in Treating Patients with Rheumatologic Disease
Permalink:
Table of contents
- Article
- Summary
- BIOSIMILARS ARE NOT COMPARABLE TO GENERIC DRUGS
- PATENT EXPIRATIONS AND ECONOMIC BENEFITS FOR MANUFACTURERS DRIVE BIOSIMILAR DEVELOPMENT
- CHANGES IN MANUFACTURE OF BIOPHARMACEUTICALS
- EMA AND FDA GUIDANCE ON BIOSIMILAR STUDIES
- CLINICAL TRIAL DESIGN SUPPORTING NEW DRUG LICENSING AND BIOSIMILARS DIFFERS
- EXTRAPOLATED DATA MAY BE USED TO SUPPORT BIOSIMILAR USE
- CONCERNS REGARDING BIOSIMILAR USE FOR PATIENTS AND RHEUMATOLOGISTS: SWITCHING VERSUS SUBSTITUTION OF BIOSIMILARS MAY REQUIRE FURTHER TESTING
- ORPHAN DRUGS IN RHEUMATOLOGIC DISEASES
- ANTICIPATED FINANCIAL LOSSES CAUSED REGULATORY AGENCIES TO PROVIDE FINANCIAL INCENTIVES TO DRUG COMPANIES
- REQUIREMENTS FOR ORPHAN DRUG STATUS
- Info & Metrics
- eLetters
Cited By...
- No citing articles found.